Diastolic Heart Failure, Echocardiography, Ranolazine, Tissue Doppler Ultrasound
Conditions
Brief summary
The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.
Interventions
DRUGranolazine
extended release 500 mg twice a day for two weeks
Sponsors
University of California, San Diego
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Moderate of severe diastolic dysfunction, E/Ea\>12 * Preserved systolic function * NYHA Class I-II
Exclusion criteria
* QTc \>450 msec at enrollment * Taking medications that prolong QT interval or are potent inhibitors of CYP3A * Significant coronary artery disease * Severe valvular disease * Hepatic disease * Severe kidney disease * Women of childbearing age * Prior serious ventricular arrhythmia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in E/Ea | 2 weeks |
Secondary
| Measure | Time frame |
|---|---|
| changes in mitral inflow parameters (E, A, IVRT, DT) | 2 weeks |
| Changes in tissue doppler parameters (Ea, Aa) | 2 weeks |
| Changes in pulmonary venous inflow (S, D, a reversal) | 2 weeks |
Countries
United States
Outcome results
None listed